Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CP-195,543 and Celecoxib in Rheumatoid Arthritis
NCT00424294Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Jun 2006
- Primary completion
- Dec 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing CP-195,543 + Celecoxib + MTX with Placebo + Celecoxib + MTX (2 arms). Primary endpoint: American College of Rheumatology 20% Response at 12 weeks. Started Jun 2006; status: terminated.
02
Drugs
CP-195543
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00424294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00424294.